Superior long-term survival with acceptable safety of ATG/G-CSF–based haplo-HSCT with intensified BU+MEL/TT conditioning in CR Pediatric Non-DS–AMKL - Takeaways - MDSpire

Superior long-term survival with acceptable safety of ATG/G-CSF–based haplo-HSCT with intensified BU+MEL/TT conditioning in CR Pediatric Non-DS–AMKL

  • By

  • Fei Pan

  • Jing Long

  • Xing-yu Cao

  • Yue Lu

  • Jian-ping Zhang

  • Yan-li Zhao

  • Min Xiong

  • Fang-min Pan

  • Guan-lan Yue

  • Kang Gao

  • Zhi-jie Wei

  • April 30, 2026

  • 0 min

Share

  • 1

    Intensified conditioning with BU+MEL/TT significantly improved 5-year overall survival (OS) and leukemia-free survival (LFS) in pediatric non-DS-AMKL patients transplanted in CR.

  • 2

    The study analyzed 70 pediatric non-DS-AMKL patients undergoing haplo-HSCT, comparing standard BU/CY with intensified BU+MEL/TT conditioning.

  • 3

    No significant differences in early transplant-related mortality (TRM), engraftment, or graft-versus-host disease (GVHD) were observed between the two conditioning groups.

  • 4

    Pre-transplant non-remission or partial remission status was identified as a strong adverse factor, significantly increasing relapse incidence and non-relapse mortality.

  • 5

    The findings support the use of intensified conditioning regimens in improving outcomes for high-risk pediatric non-DS-AMKL without increasing early complications.

Original Source(s)

Superior long-term survival with acceptable safety of ATG/G-CSF–based haplo-HSCT with intensified BU+MEL/TT conditioning in CR Pediatric Non-DS–AMKL

  • by Fei Pan, Jing Long, Xing-yu Cao, Yue Lu, Jian-ping Zhang, Yan-li Zhao, Min Xiong, Fang-min Pan, Guan-lan Yue, Kang Gao, Zhi-jie Wei

  • April 30, 2026

Related Content

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer